Maze Therapeutics (NASDAQ:MAZE) Sets New 52-Week High – Should You Buy?

Maze Therapeutics, Inc. (NASDAQ:MAZE) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $43.67 and last traded at $43.48, with a volume of 258852 shares. The stock had previously closed at $40.77.

Analyst Upgrades and Downgrades

MAZE has been the topic of a number of recent analyst reports. Raymond James Financial began coverage on Maze Therapeutics in a report on Thursday, November 13th. They issued an “outperform” rating and a $48.00 price objective on the stock. BTIG Research upped their price target on Maze Therapeutics from $37.00 to $46.00 and gave the company a “buy” rating in a research note on Friday. Wedbush increased their price target on Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, JPMorgan Chase & Co. upped their target price on shares of Maze Therapeutics from $27.00 to $37.00 and gave the company an “overweight” rating in a research report on Monday, September 29th. Three research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $44.50.

Maze Therapeutics Stock Performance

The company has a 50 day moving average of $38.91 and a 200-day moving average of $27.27. The stock has a market cap of $2.13 billion and a price-to-earnings ratio of -2.12.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Insider Activity

In other Maze Therapeutics news, CMO Harold Bernstein sold 25,156 shares of the stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $40.20, for a total value of $1,011,271.20. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Amy Bachrodt sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $39.15, for a total transaction of $195,750.00. Following the sale, the senior vice president owned 12,965 shares in the company, valued at $507,579.75. The trade was a 27.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 167,500 shares of company stock worth $6,774,667.

Institutional Investors Weigh In On Maze Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. purchased a new stake in shares of Maze Therapeutics during the 1st quarter worth $145,000. Ensign Peak Advisors Inc acquired a new stake in Maze Therapeutics in the second quarter valued at $227,000. Frazier Life Sciences Management L.P. raised its stake in Maze Therapeutics by 10.6% in the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after buying an additional 438,274 shares in the last quarter. Virtus Investment Advisers LLC purchased a new position in shares of Maze Therapeutics in the 2nd quarter valued at about $85,000. Finally, CW Advisors LLC acquired a new position in Maze Therapeutics in the second quarter valued at approximately $371,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.